Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.

By Pignon Jp, Michel Ducreux. New England Journal of Medicine, 2001

1,105 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/9d09689305ac931eba546f08a1e6a366139602b1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Grothey
2. A. Benson
3. D. Sargent
4. H. Hochster
5. D. Schrag
6. A. Venook
7. A. Falcone
8. S. Kopetz

Citations in the corpus

• Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. (2004, background): “Expanding the body of data gathered indicates that in metastatic disease, this combined strategy might be beneficial on the overall rate of recurrence [7, 8, 10, 11].”
• Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. (2009, background): “78).(23) This finding reinforces the potential benefit of expanded incorporation of hepatic resection.”
• Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. (2007, methodology): “On the basis of these results, the Gruppo Oncologico Nord Ovest (GONO) launched a phase III randomized trial to compare the simplified FOLFOXIRI regimen to a standard combination of FU/LV and CPT-11 (FOLFIRI) that had demonstrated improved efficacy in comparison to FU/LV.(3)”
• Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials (2011, unknown): “In an intent-to-treat analysis, IFL resulted in significantly longer progression-free survival and overall survival than Irinotecan alone and 5FU/LV (Saltz et al., 2000).”
• Recommended guidelines for the treatment of cancer treatment-induced diarrhea. (2004, background): “In both trials, the early death rate in the IFL arm was approximately two-fold higher than in the control arm and fivefold higher (with non-overlapping 95% CIs) than the 0.9% early death rate reported by Saltz et al.8 The increase in treatment-related deaths was of particular concern because patient”
• Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial (2017, background): “agent was found to have improved the median overall survival from 12 to 15 months.(2) Since then, combination thera-”